I have received an e-mail from Biogen that seems to be promoting Zinbryta. However, it looks more like a warning against taking it.
The message begins:
Because of the risk of serious liver problems (including autoimmune-related liver problems) and other immune system problems, ZINBRYTA is only available through a restricted program called the ZINBRYTA Risk Evaluation and Mitigation Strategy (REMS) Program.
Even its potential benefits are carefully worded: Zinbryta "may decrease the number of flare-ups (relapses)," "may reduce the number of brain lesions."
Then follows a long segment called "Important Safety Information."
And that is pretty much all there is to the message, except for the very large print statement: "Introducing Zinbryta--a once-a-month self-injection for relapsing MS."
It looks to me as if about all that Zinbryta has to recommend it is that it is self-injected once a month, for those who are finding those pesky Avonex or Rebif or Copaxone injections too bothersome and are willing to take the risks of Zinbryta.
For there is this statement:
Because of its risks, ZINBRYTA is generally used in people who have tried 2 or more MS medicines that have not worked well enough.
The message was signed "Sincerely" from "your Biogen and AbbVie Service Team."